Popular
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CEBeyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
The Convergence"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Programs
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CEBeyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
AudioAbstractsAre E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
FcRn: Same Class, Different Paths—Spot Agent Differentiators
MinuteCE®FcRn: Same Class, Different Paths—Spot Agent Differentiators
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
MinuteCE®When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
CardiologyEvolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Clinical Practice
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Leveraging CGM to Its Full Potential in People with T2D
CME/CELeveraging CGM to Its Full Potential in People with T2D
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Targeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
CardiologyTargeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
Turning Flares Into Function: Flag Uncontrolled Disease
MinuteCE®Turning Flares Into Function: Flag Uncontrolled Disease
Doctors Lounge
“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
The Convergence“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
The Convergence"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
Uncovering Disparities in Teleneurology Utilization Post-Pandemic
On the Frontlines of Multiple SclerosisUncovering Disparities in Teleneurology Utilization Post-Pandemic
Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
Project Oncology®Selecting Patients for Novel Breast Cancer Imaging Modalities: The Role of AI
"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
The Convergence"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
Messy Labs, Major Breakthroughs: The Happy Accidents That Shaped Modern Medicine
Rub Some Dirt In ItMessy Labs, Major Breakthroughs: The Happy Accidents That Shaped Modern Medicine
CME
Cracking the Code of Obstruction: Unmet Needs in oHCM
MinuteCE®Cracking the Code of Obstruction: Unmet Needs in oHCM
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CEChairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Applying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome
CME/CEApplying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Industry Feature
Neuroplasticity: A Potential Target for the Treatment of Depression
Medical Industry FeatureNeuroplasticity: A Potential Target for the Treatment of Depression
Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Medical Industry FeatureAgitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Targeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Medical Industry FeatureTargeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Breakthrough Technology Improves Concussion Assessment and Player Safety
Medical Industry FeatureBreakthrough Technology Improves Concussion Assessment and Player Safety
Improving Outcomes and Reducing Delays in Orthopedic Surgery
Medical Industry FeatureImproving Outcomes and Reducing Delays in Orthopedic Surgery
Rethinking Cardiovascular Risk: Uncovering the Blind Spots
Conversations in CV Risk AssessmentRethinking Cardiovascular Risk: Uncovering the Blind Spots